The latest results from the CATIE trial indicate that treatment with Trilafon (perphenazine) is not only much cheaper than treatment with SGAs (second generation antipsychotics), but leads to superior overall quality of life for patients.
Only after thinking long and hard about it, according to the long anticipated results from the CATIE-AD trial. In this study, 421 patients with Alzheimer’s Disease were randomized to double-blind treatment with Zyprexa (mean dose, 3.2 mg/day), Seroquel (34.1 mg/day), Risperdal (0.7 mg/day), or placebo.
In the largest ever randomized controlled trial of acupuncture for depression, the treatment did no better than “non-specific” needling; in fact, it did somewhat worse.
It’s been a bad, bad year for Topamax (topiramate). First, the results of four controlled trials of Topamax as monotherapy for mania showed that it outperforms placebo in only two ways: more paresthesia and more weight loss (Kushner et al, Bipolar Disorders 2006;8:15-27).
I know that you published a famous meta-analysis several years ago in which you compared the remission rates of patients on venlafaxine with SSRIs and placebo. Can you remind us of what that study showed?
It's another hectic day in the office. You are evaluating a complicated new patient, who presents with multiple medical and psychiatric problems. Over the next 50 minutes, you're going to have to make a number of medication decisions, and you don't have the time to dig around in your bookcase, nor have you spent enough time in the gym to be able to heave around your PDR. You need all the relevant information in one spot, and you'd prefer to access it while you are sitting and talking to your patient.